Genpharmasec

Listed
Pharmaceutical products and services are provided and distributed.

About Genpharmasec

Genpharmasec is a publicly listed company. Pharmaceutical products and services are provided and distributed. The company has 10 employees. Its Indian entity Genpharmasec Limited reported revenue of ₹143 Cr. Genpharmasec offers products and services including Pharmaceutical Products and Compliance Services. Its focus areas include Traditional Pharmaceuticals.

Company details

Genpharmasec was incorporated in 1992 as a public limited company within the pharmaceutical sector. Operations are centered on the development and distribution of pharmaceutical products, with efforts directed toward expanding the product portfolio and increasing trade. The company is overseen by a team of experienced executives, including a designated Company Secretary and Compliance Officer. Focus remains on core pharmaceutical services without specified geographic limitations.

  • Employees 10
  • Stage Public
  • Sectors
    Healthcare
  • Website genpharmasec.com
  • Legal Name Genpharmasec Limited
Key Metrics
  • Market Cap
    ₹59.80 Cr

    GENPHARMA · BSE

  • Share Price
    ₹1.05

    -2.78% today

  • Revenue
    ₹140 Cr

    FY 2025-26 · +315.0% YoY

  • EBITDA
    ₹1.22 Cr

    Margin 0.9%

  • Net Profit
    ₹1.60 Cr

    FY 2025-26 · +31.2% YoY

  • P/E (TTM)
    27.6x

    P/B 0.9x

  • ROE
    0.8%

    ROCE 2.5%

  • Debt / Equity
    0.31

    Interest cover -129.2x

  • Employee Count
    10

Products & Services of Genpharmasec

Genpharmasec offers a comprehensive portfolio of products and services, including Pharmaceutical Products and Compliance Services.

Pharmaceutical Products
Healthcare Products

Pharmaceutical products are manufactured and managed as part of the company's operations.

Compliance Services
Business Services

Compliance and management services are provided to support business activities.

Board of directors of Genpharmasec Limited (Genpharmasec)

Genpharmasec Limited is the primary company behind Genpharmasec. The board of Genpharmasec Limited currently have 7 directors; the longest-serving is Rajesh Mirchumal Sadhwani, appointed in 2019. 20 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Rajesh Mirchumal Sadhwani
DIN 08315182
Director02 Jan 20197 yrs 10 moGenpharmasec Limited
Sneha Sadhwani
DIN 08315181
Director02 Jan 20197 yrs 10 moGenpharmasec Limited
Siddhesh Shankar Shende
DIN 09629926
Director04 Jul 20224 yrs 4 moGenpharmasec Limited
Mayur Bharatbhai Bhatt
DIN 08715614
Director01 Nov 20224 yrsGenpharmasec Limited
Sachin Prakash Aphandkar
DIN 08715329
Director01 Nov 20224 yrsGenpharmasec Limited
Hardik Pravinbhai Makwana
DIN 09103236
Company Secretary27 Mar 20242 yrs 7 moGenpharmasec Limited
Sohan Chaturvedi
DIN 09629728
Whole-time director26 Apr 20242 yrs 6 moGenpharmasec Limited

IPO & Listings of Genpharmasec

Genpharmasec is a publicly listed company on the BSE with ticker symbol GENPHARMA in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date15 Apr 1996
  • Listed onBSE: 531592
  • Listed entityGenpharmasec Limited
  • Exchange sectorProcess industries
  • ISININE861N01036
  • Share price₹1.02 (+2% on the day) · 2026-10-14
  • Market capitalisation₹55.4 Cr
  • Price to earnings137.5
  • EPS (diluted, trailing year)₹-0.00
  • Volume (last session)163,220

Financials of Genpharmasec

Exchange-reported figures of Genpharmasec Limited, the listed company behind Genpharmasec (BSE: GENPHARMA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹140 Cr
+315.0% YoY
EBITDA
₹1.22 Cr
+1642.9% YoY
Profit After Tax
₹1.60 Cr
+31.1% YoY
Net Worth
₹66.26 Cr
+1.7% YoY
Total Assets
₹101 Cr
+42.7% YoY
Total Debt
₹34.95 Cr
+561.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Income statement
Revenue14033.7230.4125.52
Revenue growth+315.0%+10.9%+19.2%-
EBITDA1.220.070.060.26
EBITDA margin+0.9%+0.2%+0.2%+1.0%
Profit before tax0.971.870.270.28
Net profit1.601.22(0.15)1.12
Net profit margin+1.1%+3.6%-0.5%+4.4%
EPS (₹)0.010.020.000.04
Balance sheet
Total assets10170.5768.4218.41
Net worth66.2665.1664.3915.33
Total debt34.955.283.893.08
Cash & bank10.075.2718.831.99
Net working capital43.1017.1136.5816.51
Cash flow
Cash from operations(17.55)2.95(2.95)(3.06)
Cash from investing13.26(4.22)(28.06)0.36
Cash from financing3.92(1.25)47.853.08
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue85.6649.7155.4339.8332.6412.0414.018.48
Revenue growth (YoY)+162.4%+312.9%+295.7%+369.7%+441.3%+131.5%--
Other income1.060.371.020.980.460.690.940.81
EBITDA1.640.961.99(1.24)(0.47)0.94(1.00)0.71
EBITDA margin+1.9%+1.9%+3.6%-3.1%-1.4%+7.8%-7.1%+8.4%
Depreciation0.680.670.680.670.560.270.260.10
Interest0.440.400.480.410.230.120.110.16
Profit before tax1.580.261.85(1.34)(0.80)1.24(0.43)1.26
Tax0.550.430.50(0.50)0.380.03(0.16)0.51
Net profit1.03(0.17)1.35(0.84)(1.18)1.21(0.27)0.75
EPS (₹)0.010.000.02(0.02)(0.02)0.02(0.01)0.01
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue13132.9630.4125.5227.3221.3116.50
Revenue growth+298.5%+8.4%+19.2%-6.6%+28.2%+29.2%-
EBITDA2.420.440.180.26(0.51)1.190.64
EBITDA margin+1.8%+1.3%+0.6%+1.0%-1.9%+5.6%+3.9%
Profit before tax6.443.450.490.28(0.43)1.511.20
Net profit5.462.470.071.12(0.20)1.261.00
Net profit margin+4.2%+7.5%+0.2%+4.4%-0.7%+5.9%+6.1%
EPS (₹)0.100.040.000.04(0.01)0.050.05
Balance sheet
Total assets76.5469.9867.7818.4115.3720.6619.03
Net worth71.4966.5564.5715.3315.3720.6719.04
Total debt4.983.433.213.080.000.000.00
Cash & bank9.295.1418.581.991.613.532.58
Net working capital28.2717.8235.6516.5112.8211.957.87
Cash flow
Cash from operations1.930.96(2.27)(3.06)(2.34)(2.13)1.39
Cash from investing(1.64)(2.92)(29.03)0.360.42(1.41)(4.01)
Cash from financing(0.02)(0.44)47.893.080.004.500.00
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue50.8344.7851.6636.0131.5612.1113.568.34
Revenue growth (YoY)+61.1%+269.8%+281.0%+331.8%+447.0%+128.5%--
Other income1.660.971.621.431.000.821.060.93
Total expenses49.1843.4350.0836.6831.0611.1114.557.40
EBITDA1.651.351.58(0.67)0.501.00(0.99)0.94
EBITDA margin+3.2%+3.0%+3.1%-1.9%+1.6%+8.3%-7.3%+11.3%
Depreciation0.100.100.090.070.040.040.040.05
Interest0.160.130.250.190.080.080.060.11
Profit before tax3.052.092.860.501.381.70(0.03)1.71
Tax0.490.530.55(0.27)0.570.150.200.61

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 19 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue85.6649.7155.4339.8332.6412.0414.018.48
Revenue growth (YoY)+162.4%+312.9%+295.7%+369.7%+441.3%+131.5%--
Other income1.060.371.020.980.460.690.940.81
EBITDA1.640.961.99(1.24)(0.47)0.94(1.00)0.71
EBITDA margin+1.9%+1.9%+3.6%-3.1%-1.4%+7.8%-7.1%+8.4%
Depreciation0.680.670.680.670.560.270.260.10
Interest0.440.400.480.410.230.120.110.16
Profit before tax1.580.261.85(1.34)(0.80)1.24(0.43)1.26
Tax0.550.430.50(0.50)0.380.03(0.16)0.51
Net profit1.03(0.17)1.35(0.84)(1.18)1.21(0.27)0.75
EPS (₹)0.010.000.02(0.02)(0.02)0.02(0.01)0.01
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Revenue14033.7230.4125.52
Revenue growth+315.0%+10.9%+19.2%-
Other income3.163.060.660.10
Total expenses13933.6530.3525.26
Employee cost0.000.990.760.54
EBITDA1.220.070.060.26
EBITDA margin+0.9%+0.2%+0.2%+1.0%
Depreciation2.170.810.040.02
Interest1.240.450.410.06
Profit before tax0.971.870.270.28
Tax0.410.650.42(0.84)
Net profit1.601.22(0.15)1.12
Net profit margin+1.1%+3.6%-0.5%+4.4%
EPS (₹)0.010.020.000.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Equity & liabilities
Share capital55.3755.3755.3727.69
Reserves & surplus10.899.799.02(12.36)
Shareholders' funds (net worth)66.2665.1664.3915.33
Minority interest(0.62)0.120.140.00
Secured loans1.080.000.000.00
Unsecured loans33.875.283.893.08
Total debt34.955.283.893.08
Total liabilities10170.5768.4218.41
Assets
Gross block47.848.480.930.15
Net block41.257.590.830.10
Capital work in progress0.000.000.000.00
Investments1.5819.7319.320.95
Inventories13.887.308.849.68
Sundry debtors29.2713.609.105.71
Cash & bank balances10.075.2718.831.99
Loans & advances27.300.252.510.59
Total current assets80.5226.4239.2817.97
Total current liabilities37.429.312.701.46
Net working capital43.1017.1136.5816.51
Total assets10170.5768.4218.41
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Opening cash1.343.171.991.61
Net cash from operating activities(17.55)2.95(2.95)(3.06)
Net cash from investing activities13.26(4.22)(28.06)0.36
Net cash from financing activities3.92(1.25)47.853.08
Net change in cash(0.37)(2.52)16.840.39
Closing cash10.075.2718.831.99
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Growth
Sales growth+315.0%+10.9%+19.2%-
EBITDA growth+1642.9%+16.7%-76.9%-
PBT growth-56.8%+722.2%-3.6%+9997.0%
Net income growth+31.2%+913.3%-113.4%-
Revenue CAGR (3Y)+76.3%---
EBITDA CAGR (3Y)+67.0%---
Profitability & leverage
Net income margin+0.4%+4.7%-0.5%+4.4%
Return on capital employed+2.5%+3.7%0.0%+1.5%
Return on net worth+0.8%+2.4%0.0%+5.6%
Debt / equity0.310.070.090.20
Long-term debt / equity0.230.070.080.16
Interest cover-129.17-104.882,050.0025.00
Efficiency & per share
Fixed asset turnover4.977.1756.31170.13
Inventory turnover13.214.183.282.64
Debtors turnover6.532.974.114.47
EPS (₹)0.030.030.000.04
Dividend per share (₹)0.000.000.000.00
Book value per share (₹)1.201.181.160.55
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue50.8344.7851.6636.0131.5612.1113.568.34
Revenue growth (YoY)+61.1%+269.8%+281.0%+331.8%+447.0%+128.5%--
Other income1.660.971.621.431.000.821.060.93
Total expenses49.1843.4350.0836.6831.0611.1114.557.40
EBITDA1.651.351.58(0.67)0.501.00(0.99)0.94
EBITDA margin+3.2%+3.0%+3.1%-1.9%+1.6%+8.3%-7.3%+11.3%
Depreciation0.100.100.090.070.040.040.040.05
Interest0.160.130.250.190.080.080.060.11
Profit before tax3.052.092.860.501.381.70(0.03)1.71
Tax0.490.530.55(0.27)0.570.150.200.61
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue13132.9630.4125.5227.3221.3116.50
Revenue growth+298.5%+8.4%+19.2%-6.6%+28.2%+29.2%-
Other income4.873.430.720.100.090.330.56
Total expenses12932.5230.2325.2627.8320.1215.86
Employee cost0.000.670.760.540.250.190.13
EBITDA2.420.440.180.26(0.51)1.190.64
EBITDA margin+1.8%+1.3%+0.6%+1.0%-1.9%+5.6%+3.9%
Depreciation0.260.130.020.020.010.010.00
Interest0.590.290.390.060.000.000.00
Profit before tax6.443.450.490.28(0.43)1.511.20
Tax0.980.980.42(0.84)(0.23)0.250.20
Net profit5.462.470.071.12(0.20)1.261.00
Net profit margin+4.2%+7.5%+0.2%+4.4%-0.7%+5.9%+6.1%
EPS (₹)0.100.040.000.04(0.01)0.050.05
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital55.3755.3755.3727.6927.6927.6921.69
Reserves & surplus16.1211.189.20(12.36)(12.32)(7.02)(4.15)
Shareholders' funds (net worth)71.4966.5564.5715.3315.3720.6719.04
Secured loans0.000.000.000.000.000.000.00
Unsecured loans4.983.433.213.080.000.000.00
Total debt4.983.433.213.080.000.000.00
Total liabilities76.5469.9867.7818.4115.3720.6619.03
Assets
Gross block1.240.450.170.150.140.070.05
Net block1.130.360.100.100.110.050.04
Capital work in progress0.000.000.000.000.000.000.00
Investments21.6720.8419.520.952.457.815.76
Inventories12.587.248.849.689.897.683.46
Sundry debtors28.0213.399.105.716.457.527.03
Cash & bank balances9.295.1418.581.991.613.532.58
Loans & advances11.891.161.830.591.150.380.53
Total current assets61.7826.9338.3517.9719.1019.1113.60
Total current liabilities33.519.112.701.466.287.165.73
Net working capital28.2717.8235.6516.5112.8211.957.87
Total assets76.5469.9867.7818.4115.3720.6619.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.522.921.991.613.532.585.20
Net cash from operating activities1.930.96(2.27)(3.06)(2.34)(2.13)1.39
Net cash from investing activities(1.64)(2.92)(29.03)0.360.42(1.41)(4.01)
Net cash from financing activities(0.02)(0.44)47.893.080.004.500.00
Net change in cash0.27(2.39)16.590.39(1.93)0.96(2.62)
Closing cash9.295.1418.581.991.613.532.58
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+298.5%+8.4%+19.2%-6.6%+28.2%+29.2%-
EBITDA growth+450.0%+144.4%-30.8%+151.0%-142.9%+85.9%-
PBT growth+70.6%+669.4%+75.0%+9998.0%-+25.8%+328.6%
Net income growth+121.1%+3428.6%-93.8%+660.0%-115.9%+26.0%-
Revenue CAGR (3Y)+72.7%+6.5%+12.6%+15.7%+315.8%+543.4%+225.2%
EBITDA CAGR (3Y)+110.1%--46.7%-25.9%+78.3%--
Profitability & leverage
Net income margin+4.2%+8.5%+0.2%+4.4%-0.7%+5.9%+6.1%
Return on capital employed+9.5%+5.6%+1.8%+1.8%0.0%+7.6%+5.8%
Return on net worth+7.8%+4.1%+0.1%+6.4%0.0%+6.4%+4.9%
Debt / equity0.060.050.080.100.000.000.00
Long-term debt / equity0.060.050.070.080.000.000.00
Interest cover27.4445.16243.7525.000.000.000.00
Efficiency & per share
Fixed asset turnover155.44106.32190.06176.00260.19355.17550.00
Inventory turnover13.254.103.282.613.113.839.54
Debtors turnover6.342.934.114.203.912.934.67
EPS (₹)0.100.050.000.04(0.01)0.050.05
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)1.291.201.170.550.560.750.81
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Genpharmasec

Premium access

Complete news archive for Genpharmasec

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Genpharmasec

Genpharmasec has 10 employees.

The primary company behind Genpharmasec, Genpharmasec Limited, reported revenue of ₹143 Cr for FY 2026, up 315% year on year.

Genpharmasec was incorporated in 1992 as a public limited company within the pharmaceutical sector. Operations are centered on the development and distribution of pharmaceutical products, with efforts directed toward expanding the product portfolio and increasing trade. The company is overseen by a team of experienced executives, including a designated Company Secretary and Compliance Officer. Focus remains on core pharmaceutical services without specified geographic limitations.

Genpharmasec offers Pharmaceutical Products and Compliance Services.

Yes, Genpharmasec is publicly traded on BSE under the ticker symbol GENPHARMA.

Genpharmasec operates through Genpharmasec Limited.

The legal entities of Genpharmasec currently have 7 directors, including Mayur Bharatbhai Bhatt, Sachin Prakash Aphandkar, Hardik Pravinbhai Makwana and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available